Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: Novel regulation of the estrogen receptor

Endocrinology

Volumn 154, Issue 5, 2013, Pages 1780-1793

  Foulstone, Emily J ^a   Zeng, Li ^a   Perks, Claire M ^a   Holly, Jeff M P ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; INTEGRIN RECEPTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 2; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL COUNT; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; GENE SILENCING; MITOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MAMMARY GLANDS, HUMAN; PTEN PHOSPHOHYDROLASE; RNA, SMALL INTERFERING;

EID: 84876753114     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1970     Document Type: Article

References (46)

1. Dickler MN. Targeting the insulin-like growth factor pathway in estrogen receptor-positive breast cancer: a bumpy start with an uncertain future. J Clin Oncol. 2011;29:3846-3848.
2. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451-1467.
3. Perks CM, Holly JM. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mamm Gland Biol Neoplasia. 2008;13: 455-469.
4. el Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B, Pommier G. Alterations in serum levels of insulin-like growth factors and insulinlike growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer. 1994;57:491-497.
5. Karasik A, Menczer J, Pariente C, Kanety H. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab. 1994;78: 271-276.
6. Baron-Hay S, Boyle F, Ferrier A, Scott C. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res. 2004;10:1796-1806.
7. Lee DY, Kim SJ, Lee YC. Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Kor Med Sci. 1999;14:401-404.
8. Cohen P, PeehlDM,Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab. 1993;76:1031-1035.
9. Shariat SF, Lamb DJ, KattanMW,et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002;20:833-841.
10. Gronbaek H, Flyvbjerg A, Mellemkjaer L, et al. Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomark Prev. 2004;13:1759-1764.
11. Keinan-Boker L, BuenoDeMesquitaHB,Kaaks R, et al. Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer. 2003;106:90-95.
12. Busund LT, Richardsen E, Busund R, et al. Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol. 2005;58:361-366.
13. So AI, Levitt RJ, Eigl B, et al. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res. 2008;14:6944-6954.
14. Martin JL, Baxter RC. Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology. 2007;148:2532-2541.
15. Mireuta M, Darnel A, Pollak M. IGFBP-2 expression in MCF-7 cells is regulated by thePI3K/AKT/mTORpathway through Sp1-induced increase in transcription. Growth Factors. 2010;28:243-255.
16. Kiyama S, Morrison K, Zellweger T, et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res. 2003;63:3575-3584.
17. Uzoh CC, Holly JM, Biernacka KM, et al. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGFdependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer. 2011;104:1587-1593.
18. Kiepe D, Van Der Pas A, Ciarmatori S, et al. Defined carboxyterminal fragments of insulin-like growth factor (IGF) binding protein-2 exert similar mitogenic activity on cultured rat growth plate chondrocytes as IGF-I. Endocrinology. 2008;149:4901-4911.
19. Schutt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW.Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol. 2004;32:859-868.
20. Pereira JJ, Meyer T, Docherty SE, et al. Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with -v-3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res. 2004;64:977-984.
21. Perks CM, Vernon EG, Rosendahl AH, Tonge D, Holly JM. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene. 2007;26:5966-5972.
22. Zeng L, Biernacka KM, Holly JM, et al. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocr Relat Cancer. 2010;17:539-551.
23. Morgan L, Gee J, Pumford S, et al. Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther. 2009;8:1550-1558.
24. McIntosh J, Dennison G, Holly JM, et al. IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin. J Biol Chem. 2010;285: 38788-38800.
25. Chaudhri RA, Olivares-Navarrete R, Cuenca N, Hadadi A, Boyan BD, Schwartz Z. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ER-36). J Biol Chem. 2012;287:7169-7181.
26. Sisci D, Middea E, Morelli C, et al. 17-estradiol enhances -(5) integrin subunit gene expression through ER-α-Sp1 interaction and reduces cell motility and invasion of ER-α-positive breast cancer cells. Breast Cancer Res Treat. 2010;124:63-77.
27. Stoica A, Saceda M, Fakhro A, Joyner M, Martin MB. Role of insulin-like growth factor-I in regulating estrogen receptor-α gene expression. J Cell Biochem. 2000;76:605-614.
28. Holmes KM, Annala M, Chua CY, et al. Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-αB network. Proc Natl Acad Sci USA. 2012;109:3475-3480.
29. Kim DS, Cho HJ, Yang SK, Shin JW, Huh CH, Park KC. Insulin-like growth factor-binding protein contributes to the proliferation of less proliferative cells in forming skin equivalents. Tissue Eng Part A. 2009;15:1075-1080.
30. Juncker-Jensen A, Lykkesfeldt AE, Worm J, Ralfkiaer U, Espelund U, Jepsen JS. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Horm IGF Res. 2006;16:224-239.
31. Migita T, Narita T, Asaka R, et al. Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. Am J Pathol. 2010;176:1756-1766.
32. Conover CA, Khosla S. Role of extracellular matrix in insulin-like growth factor (IGF) binding protein-2 regulation of IGF-II action in normal human osteoblasts. Growth Horm IGF Res. 2003;13:328-335.
33. Russo VC, Bach LA, Fosang AJ, Baker NL, Werther GA. Insulin-like growth factor binding protein-2 binds to cell surface proteoglycans in the rat brain olfactory bulb. Endocrinology. 1997;138:4858-4867.
34. Russo VC, Schutt BS, Andaloro E, et al. Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology. 2005;146:4445-4455.
35. Miyako K, Cobb LJ, Francis M, et al. PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions. Mol Endocrinol. 2009;23:169-175.
36. Hoeflich A, Reisinger R, Schuett BS, et al. Peri/nuclear localization of intact insulin-like growth factor binding protein-2 and a distinct carboxyl-terminal IGFBP-2 fragment in vivo. Biochem Biophys Res Commun. 2004;324:705-710.
37. Terrien X, Bonvin E, Corroyer S, Tabary O, Clement A, Henrion Caude A. Intracellular colocalization and interaction of insulin-like growth factor binding protein-2 with the cyclin-dependent kinase inhibitor p21 CIP/WAF1 during growth inhibition. Biochem J. 2005;392(Pt 3):457-465.
38. Burrows C, Holly JM, Laurence NJ, et al. Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. Endocrinology. 2006;147:3484-3500.
39. MengR,TangHY,Westfall J, et al. Crosstalk between integrin-v-3 and estrogen receptor-α is involved in thyroid hormone-induced proliferation in human lung carcinoma cells. PLoS One. 2011;6: e27547.
40. Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology. 1990;127:2679-2686.
41. Takeo C, Ikeda K, Horie-Inoue K, Inoue S. Identification of Igf2, Igfbp2 and Enpp2 as estrogen-responsive genes in rat hippocampus. Endocr J. 2009;56:113-120.
42. Probst-Hensch NM, Steiner JH, Schraml P, et al. IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clin Cancer Res. 2010;16: 1025-1032.
43. Perks CM, Gill ZP, Newcomb PV, Holly JM. Activation of integrin and ceramide signalling pathways can inhibit the mitogenic effect of insulin-like growth factor I (IGF-I) in human breast cancer cell lines. Br J Cancer. 1999;79:701-706.
44. Lee SH, Nam HS. TNF -induced down-regulation of estrogen receptor-in MCF-7 breast cancer cells. Mol Cells. 2008;26:285-290.
45. Adam RM, Mukhopadhyay NK, Kim J, et al. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res. 2007;67:6238-6246.
46. Del Pozo MA. Integrin signaling and lipid rafts. Cell Cycle. 2004;3:725-728.